BBPvsXPHETF Comparison
VS
Virtus LifeSci Biotech Products ETF (BBP) belongs to the Tomorrow's Treatments segment. State Street SPDR S&P Pharmaceuticals ETF (XPH) is part of the US Health Care segment. Both ETFs have the same top 1 sector exposures: Healthcare. BBP is less expensive with a Total Expense Ratio (TER) of 0.34%, versus 0.35% for XPH. BBP is up 28.37% year-to-date (YTD) with +$66M in YTD flows. XPH performs worse with 12.48% YTD performance, and +$186M in YTD flows. Run a side-by-side ETF comparison of BBP and XPH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
BBP vs XPH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 10/26/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | BBP XPH | -2.65%-5.82% | +5.62%-8.05% | +28.37%+12.48% | +38.01%+28.86% | +119.28%+80.65% | +100.33%+39.77% |
| Flows | BBP XPH | --$80M | +$26M+$11M | +$66M+$186M | +$78M+$206M | +$83M+$160M | +$76M+$157M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | BBP XPH | +28.32%+22.75% | +26.44%+23.36% | +24.98%+20.82% | +26.86%+21.10% |
| Max drawdown | BBP XPH | -8.70%-16.58% | -9.59%-16.58% | -25.54%-23.45% | -37.61%-30.87% |
| Max drawdown duration | BBP XPH | 68d68d | 48d68d | 292d322d | 586d1452d |
Trading data
BBP | XPH | |
Last sale 10/27/2026 at 1:30 PM | $104.89 | $63.96 |
| Previous close 10/26/2026 | $102.33 | $62.90 |
| Consolidated volume 10/26/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of September 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
BBP | XPH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 10/27/2026 at 1:30 PM
Live
Closed
BBP | XPH | |
|---|---|---|
| Last price | $104.89 | $63.96 |
| 1D performance | +2.50% | +1.69% |
| AuM | $127.99 M | $440.44 M |
| E/R | 0.34% | 0.35% |
Characteristics
BBP | XPH | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | VIRTUS Investment Partners | State Street Investment Management |
| Benchmark | LifeSci Biotechnology Products Index | S&P Pharmaceuticals Select Industry Index |
| N° of holdings | 66 | 62 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 16, 2014 | June 19, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
BBP
USA
85.98%
Other
14.02%
XPH
USA
89.77%
Other
10.23%
Sectors
BBP
Healthcare
98.44%
Other
1.56%
XPH
Healthcare
93.27%
Other
6.73%
Advertisement
Diversification
BBP
Total weight of top 15 holdings out of 15
31.08%
XPH
Total weight of top 15 holdings out of 15
34.13%
Top 15 holdings
Data as of August 31, 2026
BBP
Moderna, Inc.
3.58%
Crinetics Pharmaceuticals, Inc.
2.94%
Omeros Corp.
2.49%
Iovance Biotherapeutics, Inc.
2.36%
Verastem, Inc.
2.15%
Precigen, Inc.
1.99%
Halozyme Therapeutics, Inc.
1.84%
Zai Lab Ltd.
1.82%
Kiniksa Pharmaceuticals International Plc
1.81%
Kura Oncology, Inc.
1.72%
BeOne Medicines Ltd.
1.70%
Rigel Pharmaceuticals, Inc.
1.69%
Nuvation Bio, Inc.
1.69%
ACADIA Pharmaceuticals, Inc.
1.67%
Protagonist Therapeutics, Inc.
1.65%
XPH
Amylyx Pharmaceuticals, Inc.
3.65%
Crinetics Pharmaceuticals, Inc.
3.60%
MBX Biosciences, Inc.
2.89%
Omeros Corp.
2.68%
Enliven Therapeutics, Inc.
2.28%
Nuvation Bio, Inc.
2.12%
Corcept Therapeutics, Inc.
2.11%
Eton Pharmaceuticals, Inc.
2.08%
Perrigo Co. Plc
1.91%
Edgewise Therapeutics, Inc.
1.85%
Nektar Therapeutics
1.83%
Merck & Co., Inc.
1.81%
Trevi Therapeutics, Inc.
1.80%
Tarsus Pharmaceuticals, Inc.
1.76%
Bristol Myers Squibb Co.
1.75%
Frequently asked questions about BBP and XPH
How have the BBP and XPH ETFs performed in 2026?
As of October 26, 2026, BBP is up 28.37% year-to-date (YTD), while XPH has returned 12.48%. That puts BBP better performer ahead so far this year.
Which ETF is attracting more investor money: BBP or XPH?
Year-to-date, the BBP ETF saw +$66M in flows, compared to +$186M for XPH.
Which ETF is more volatile: BBP or XPH?
Over the past year, BBP had a volatility of 26.44%, while XPH experienced 23.36%.
Which ETF is bigger: BBP or XPH?
As of October 26, 2026, BBP holds $127.99 M in assets under management (AUM), while XPH manages $440.44 M.
What sectors do the BBP and XPH ETFs invest in?
BBP leans toward sectors like Healthcare. Meanwhile, XPH focuses on Healthcare.
What are the top holdings of the BBP ETF and XPH ETF?
BBP top holdings include Moderna, Inc., Crinetics Pharmaceuticals, Inc. and Omeros Corp.. XPH holds in its top three: Amylyx Pharmaceuticals, Inc., Crinetics Pharmaceuticals, Inc. and MBX Biosciences, Inc..
Which ETF is more diversified: BBP or XPH?
BBP holds 66 securities with 31.08% of its assets in the top 15. XPH has 62 securities and a top 15 weight of 34.13%.
Advertisement
Latest news about BBP & XPH
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Advertisement
Advertisement
